Challenges and opportunities in microRNA-based cancer therapeutics
The 2024 Nobel Prize honored groundbreaking microRNA (miRNA) discoveries that unveiled the critical functions of miRNAs in fundamental biology and human health. Despite promising therapeutic potential, there are no Food and Drug Administration (FDA)-approved miRNA-based cancer therapies. This commentary discusses the progress and challenges of miRNA-based cancer therapeutics and their potential impact on future clinical oncology.
Authors
- Jingfang Ju (ORCID: https://orcid.org/0000-0002-4821-7458)
Institutions
- Stony Brook School (US)
Publication Details
- Journal
- Cell Reports Medicine
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1016/j.xcrm.2025.102057
- Citations
- 14
- Primary Topic
- MicroRNA in disease regulation
- Type
- article
- Field-Weighted Citation Impact
- 13.11
Funders
- U.S. Department of Veterans Affairs
- Office of Academic Affiliations, Department of Veterans Affairs